Nanoencapsulation in lipid-core nanocapsules controls mometasone furoate skin permeability rate and its penetration to the deeper skin layers

Skin Pharmacology and Physiology

Volumn 27, Issue 4, 2014, Pages 217-228

  Melero, Ana ^a,b   Ferreira Ourique, Aline ^d   Stanisçuaski Guterres, Silvia ^d,e   Raffin Pohlmann, Adriana ^d,e   Lehr, Claus Michael ^b,c   Ruver Beck, Ruy Carlos ^d,e   Schaefer, Ulrich ^b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Department of Biopharmaceutics and Pharmaceutical Technology ^*  (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d Programa de Pós Graduação em Nanotecnologia Farmacêutica   (Germany)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Drug release; Hydrogels; Lipid core nanocapsules; Mometasone furoate; Skin penetration; Skin permeability

Indexed keywords

CARBOMER; LIPID CORE NANOCAPSULE; MOMETASONE FUROATE; NANOCAPSULE; POLYCAPROLACTONE; UNCLASSIFIED DRUG; LIPID; POLYESTER; PREGNANE DERIVATIVE;

ARTICLE; CRYSTALLIZATION; DIFFUSION; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RELEASE; HUMAN; LASER DIFFRACTION; LIGHT SCATTERING; NANOENCAPSULATION; PARTICLE SIZE; PH; PH MEASUREMENT; PRIORITY JOURNAL; SKIN PENETRATION; SKIN PERMEABILITY; STRATUM CORNEUM; VISCOSITY; METABOLISM; PERMEABILITY; SKIN; SKIN ABSORPTION; DRUG FORMULATION;

HUMANS; LIPIDS; NANOCAPSULES; PARTICLE SIZE; PERMEABILITY; POLYESTERS; PREGNADIENEDIOLS; SKIN; SKIN ABSORPTION;

EID: 84898674481     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000354921     Document Type: Article

References (40)

1. Mora-Huertas CE, Fessi H, Elaissari A: Polymer-based nanocapsules for drug delivery. Int J Pharm 2010; 385: 113-142.
2. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE: Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70: 1-20.
3. Mohanraj VJ, Chen Y: Nanoparticles: a review. Trop J Pharm Res 2006; 5: 561-573.
4. Rahimnejad M, Mokhtarian N, Ghasemi M: Production of protein nanoparticles for food and drug delivery system. Afr J Biotechnol 2009; 8: 4738-4743.
5. Jager E, Venturini CG, Poletto FS, Colome LM, Pohlmann JPU, Bernardi A, Battastini AMO, Guterres SS, Pohlmann AR: Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. J Biomed Nanotechnol 2009; 5: 130-140.
6. Venturini CG, Jager E, Oliveira CP, Bernardi A, Battastini AMO, Guterres SS, Pohlmann AR: Formulation of lipid core nanocapsules. Colloids Surf A Physicochem Eng Asp 2011; 375: 200-208.
7. Pohlmann AR, Fonseca FN, Paese K, Detoni CB, Coradini K, Beck RCR, Guterres SS: Poly(-caprolactone) microcapsules and nanocapsules in drug delivery. Expert Opin Drug Deliv 2013; 10: 623-638.
8. Ourique AF, Azoubel S, Ferreira CV, Silva CB, Marchiori MCL, Pohlmann AR, Guterres SS, Beck RCR: Lipid-core nanocapsules as a nanomedicine for parenteral administration of tretinoin: development and in vitro antitumor activity on human myeloid leukaemia cells. J Biomed Nanotechnol 2010; 6: 214-223.
9. Frozza RL, Bernardi A, Paese K, Hoppe JB, da Silva T, Battastini AM, Pohlmann AR, Guterres SS, Salbego C: Characterization of trans-resveratrol- loaded lipid-core nanocapsules and tissue distribution studies in rats. J Biomed Nanotechnol 2010; 6: 694-703.
10. Bernardi A, Frozza RL, Jager E, Figueiro F, Bavaresco L, Salbego C, Pohlmann AR, Guterres SS, Battastini AMO: Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cells lines: an in vitro study. Eur J Pharmacol 2008; 586: 24-34.
11. Bernardi A, Zilberstein AC, Jager E, Campos MM, Morrone FB, Calixto JB, Pohlmann AR, Guterres SS, Battastini AMO: Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br J Pharmacol 2009; 158: 1104-1111.
12. Kulkamp IC, Rabelo BD, Berlitz SJ, Isoppo M, Bianchin MD, Schaffazick SR, Pohlmann AR, Guterres SS: Nanoencapsulation improves the in vitro antioxidant activity of lipoic acid. J Biomed Nanotechnol 2011; 7: 598-607.
13. Contri RV, Katzer T, Pohlmann AR, Guterres SS: Chitosan hydrogel containing capsaicinoids-loaded nanocapsules: an innovative formulation for topical delivery. Soft Mater 2010; 8: 370-385.
14. Marchiori ML, Lubini G, dalla Nora G, Friedrich RB, Fontana MC, Ourique AF, Bastos MO, Rigo LA, Silva CB, Tedesco SB, Beck RCR: Hydrogel containing dexamethasoneloaded nanocapsules for cutaneous administration: preparation, characterization, and in vitro drug release study. Drug Dev Ind Pharm 2010; 36: 962-971.
15. Fontana MC, Rezer JFP, Coradini K, Leal DBR, Beck RCR: Improved efficacy in the treatment of contact dermatitis in rats by a dermatological nanomedicine containing clobetasol propionate. Eur J Pharm Biopharm 2011; 79: 241-249.
16. Ourique AF, Melero A, de Bona da Silva C, Schaefer UF, Pohlmann AR, Guterres SS, Lehr CM, Kostka K, Beck RCR: Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicine. Eur J Pharm Biopharm 2011; 79: 95-101.
17. Brazzini B, Pimpinelli N: New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002; 3: 47-58.
18. Valotis A, Neukam K, Elert O, Hogger P: Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci 2004; 93: 1337-1350.
19. Calverley PMA, Rennard S, Nelson HS, Karpel JP, Abbate EH, Stryszak P, Staudinger H: One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res 2008; 9: 73.
20. Cao S, Ren X, Zhang Q, Chen E, Xu F, Chen J, Liu L, Jiang X: In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate. Int J Pharm 2009; 365: 109-115.
21. Valotis A, Hogger P: Human receptor kinetics and lung tissue retention of the enhancedaffinity glucocorticoid fluticasone furoate. Respir Res 2007; 8: 54.
22. Franz TJ: Percutaneous absorption: on the relevance of in vitro data. J Invest Dermatol 1975; 64: 190-195.
23. Wagner H, Kostka KH, Lehr CM, Schaefer UF: Drug distribution in human skin using two different in vitro test systems: comparison with in vivo data. Pharm Res 2000; 17: 1475-1481.
24. Jornada DS, Fiel LA, Bueno K, Gerent JF, Petzhold CL, Beck RCR, Guterres SS, Pohlmann AR: Lipid-core nanocapsules: mechanism of self-assembly, control of size and loading capacity. Soft Matter 2012; 8: 6646-6655.
25. Ourique AF, Contri RV, Guterres SS, Beck RCR, Pohlmann AR, Melero A, Schaefer UF: Set-up of a method using LC-UV to assay mometasone furoate in pharmaceutical dosage forms. Quim Nova 2012; 35: 818-821.
26. Flores FC, Ribeiro RF, Ourique AF, Rolim CMB, Silva CB, Pohlmann AR, Beck RCR, Guterres SS: Nanostructured systems containing an essential oil: protection against volatilization. Quim Nova 2001; 34: 968-972.
27. Teng XW, Cutler DC, Davies NM: Degradation kinetics of mometasone furoate in aqueous systems. Int J Pharm 2003; 259: 129-141.
28. FDA: Guidance for industry: nonsterile semisolid dosage forms. Scale-up and postapproval changes: chemistry, manufacturing and controls; in vitro release testing and in vivo bioequivalence documentation (SUPAC-SS). Rockville, FDA, 1997.
29. Siepmann J, Peppas NA: Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 2001; 48: 139-157.
30. Hahn T, Hansen S, Neumann D, Kostka KH, Lehr CM, Muys L, Schaefer UF: Infrared densitometry: a fast and non-destructive method for exact stratum corneum depth calculation for in vitro tape-stripping. Skin Pharmacol Physiol 2010; 23: 183-192.
31. Melero A, Hahn T, Schaefer UF, Schneider M: In vitro human skin segmentation and drug concentration-skin depth profiles; in Turksen K (ed): Permeability Barrier: Methods and Protocols. New York, Humana, 2011, pp 33-50.
32. Melero A, Garrigues TM, Alos M, Kostka KH, Lehr CM, Schaefer UF: Nortriptyline for smoking cessation: release and human skin diffusion from patches. Int J Pharm 2009; 378: 101-107.
33. Surti N, Naik S, Bagchi T, Dwarkanath BS, Misra A: Intracellular delivery of nanoparticles of an antiasthmatic drug. AAPS Pharm-SciTech 2008; 9: 217-223.
34. Surti N, Naik S, Misra A: Pharmacokinetic evaluation of wheat germ agglutinin-grafted nanoparticles of mometasone furoate. Sci Pharm 2009; 77: 123-132.
35. Alves MP, Pohlmann AR, Guterres SS: Semisolid topical formulations containing nimesulide-loaded nanocapsules, nanospheres or nanoemulsion: development and rheological characterization. Pharmazie 2005; 60: 900-904.
36. Siqueira NM, Contri RV, Paese K, Beck RCR, Pohlmann AR, Guterres SS: Innovative sunscreen formulation based on benzophenone-3-loaded chitosan-coated polymeric nanocapsules. Skin Pharmacol Physiol 2011; 24: 166-174.
37. Schneider M, Stracke F, Hansen F, Schaefer UF: Nanoparticles and their interactions with the dermal barrier. Dermatoendocrinol 2009; 1: 197-206.
38. Wagner H, Kostka KH, Lehr CM, Schaefer UF: Drug distribution in human skin using two different in vitro test systems: comparison with in vivo data. Pharm Res 2000; 17: 1475-1481.
39. Wagner H, Kostka KH, Lehr CM, Schaefer UF: Human skin penetration of flufenamic acid: in vivo/in vitro correlation (deeper skin layers) for skin samples from the same subject. J Invest Dermatol 2002; 118: 540-544.
40. Alves MP, Scarrone AL, Santos M, Pohlmann AR, Guterres SS: Human skin penetration and distribution of nimesulide from hydrophilic gels containing nanocarriers. Int J Pharm 2007; 341: 215-220. Nível Superior